Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Long-Term Incentive Plan awards

9 Feb 2022 07:00

RNS Number : 0870B
Diurnal Group PLC
09 February 2022
 

9 February 2022

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Issue of Long-Term Incentive Plan awards

 

On 9 February 2022, Diurnal issued a total of 2,022,447 par value options over ordinary shares of 5 pence in the Company under the Diurnal Group plc Long Term Incentive Plan (the "Plan"), of which the following were issued to persons discharging managerial responsibilities ("PDMR"):

 

PDMR

Total number of shares awarded

Type of awards

Martin Whitaker

456,521

Performance share award

Richard Bungay

374,434

Performance share award

Stewart Jones

113,043

Performance share award

John Porter

143,478

Performance share award

Richard Ross

155,899

Performance share award

 

The performance share awards will ordinarily vest no earlier than the third anniversary of their grant subject to the grantee's continued service and to the extent to which the performance conditions set for the awards are satisfied. Such awards may potentially vest until the fifth anniversary of their grant date. Performance conditions are as follows:

· Achieving a target share price of 125 pence for a three-month rolling period during the five years following grant

· Submission of a US New Drug Application (NDA) submission for Efmody® in congenital adrenal hyperplasia (CAH)

· Launch and first sales of Efmody® in Europe for adrenal insufficiency (AI) with total (AI and CAH) Efmody® cumulative sales up to 31 December 2024 in line with Company forecasts

 

The awards were granted under award agreements that incorporated the terms of the Plan. No consideration is due to be payable on vesting.

Details of the full notifications received by the Company are set out below:

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

Identification code

Ordinary shares: GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 456,521 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

Nil exercise price

456,521

d)

 

Aggregated information

- Aggregated volume

Award over 456,521 ordinary shares.

- Price

Nil price payable for grant and upon exercise

e)

 

Date of the transaction

 

9 February 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Richard Bungay

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

Identification code

Ordinary shares: GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 374,434 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

Nil exercise price

374,434

d)

 

Aggregated information

- Aggregated volume

Award over 374,434 ordinary shares.

- Price

Nil price payable for grant and upon exercise

e)

 

Date of the transaction

 

9 February 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Stewart Jones

2

 

Reason for the notification

 

a)

 

Position/status

 

Operations Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

Identification code

Ordinary shares: GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 113,043 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

Nil exercise price

113,043

d)

 

Aggregated information

- Aggregated volume

Award over 113,043 ordinary shares.

- Price

Nil price payable for grant and upon exercise

e)

 

Date of the transaction

 

9 February 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 John Porter

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Medical Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

Identification code

Ordinary shares: GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 143,478 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

Nil exercise price

143,478

d)

 

Aggregated information

- Aggregated volume

Award over 143,478 ordinary shares.

- Price

Nil price payable for grant and upon exercise

e)

 

Date of the transaction

 

9 February 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

 

Details of the person discharging managerial responsibilities / person closely associated

 

Name

 

 Richard Ross

Reason for the notification

 

Position/status

 

Chief Scientific Officer

Initial notification /Amendment

 

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

Name

 

Diurnal Group plc

LEI

 

213800I2HNUNZN1LDH29

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

Identification code

Ordinary shares: GB00BDB6Q760

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 155,899 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

Price(s) and volume(s)

Price(s)

Volume(s)

Nil exercise price

155,899

Aggregated information

- Aggregated volume

Award over 155,899 ordinary shares.

- Price

Nil price payable for grant and upon exercise

Date of the transaction

 

9 February 2022

Place of the transaction

 

Outside a trading venue

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

Corporate Broking: Rupert Dearden

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

+44 (0) 20 7710 7600

Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea, William Palmer-Brown

Corporate Broking: Nick Adams, Nick Harland

FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

Alex Davis

 

Notes to Editors

 

About Diurnal Group plc

 

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFZGGZMRDGZZZ
Date   Source Headline
30th Apr 20193:40 pmRNSHolding(s) in Company
30th Apr 20192:43 pmRNSHolding(s) in Company
26th Apr 20195:52 pmRNSDirector Dealings and Issue of Equity
26th Apr 20193:10 pmRNSHolding(s) in Company
25th Apr 20197:15 amEQSHardman & Co Research: Diurnal Group (DNL): Clarity for Chronocort regulatory pathway
24th Apr 20197:00 amRNSGrant of Orphan Drug Designation in Australia
11th Apr 20197:00 amRNSPositive Scientific Advice from EMA for Chronocort
28th Mar 20197:00 amRNSDiurnal signs marketing and distribution agreement
28th Mar 20197:00 amRNSInterim Results
20th Mar 20197:00 amRNSUpdate on Alkindi US development
25th Feb 20197:00 amRNSSubmission of MAA for Alkindi and Second Patent
11th Feb 201911:00 amRNSNotice of Interim Results
17th Jan 20197:00 amRNSDirector Dealings
16th Jan 20197:15 amEQSHardman & Co Research: Diurnal Group (DNL): Chronocort - seeking regulatory advice
10th Jan 201912:18 pmRNSStatement regarding Price Movement
10th Jan 20197:00 amRNSGrant of second US patent for Chronocort
24th Dec 20187:00 amRNSDirector Dealings and Issue of Equity
12th Dec 20184:02 pmRNSDirector Dealings
11th Dec 20187:00 amRNSRegulatory package for Scientific Advice in Europe
4th Dec 20181:08 pmRNSDirector/PDMR Shareholding
14th Nov 201811:38 amRNSResults of Annual General Meeting
14th Nov 201810:16 amRNSIssue of Equity and Exercise of Options
18th Oct 20187:15 amEQSHardman & Co Research: Diurnal Group (DNL): Unexpected Phase III trial outcome
17th Oct 20187:00 amRNSUpdate on late-stage development pipeline
8th Oct 20184:00 pmRNSPosting of Annual Report and AGM Notice
8th Oct 20182:45 pmRNSSMC Approves The Use of Alkindi
8th Oct 20187:00 amRNSHeadline Data for Chronocort European Phase III
5th Oct 20187:00 amRNSFirst patients enrolled in US Chronocort Phase III
20th Sep 20187:00 amRNSResults for the year ended 30 June 2018
15th Aug 201811:11 amRNSUpdate on Alkindi® in Germany
10th Jul 20181:36 pmRNSDirector/PDMR Shareholding
21st Jun 20187:00 amRNSNotice of Results
18th Jun 20184:54 pmRNSDirector/PDMR Shareholding
18th May 20183:33 pmRNSDirector Dealings
18th May 20181:11 pmRNSAppointment of NOMAD and Joint Broker
15th May 20188:13 amRNSLaunch of Alkindi for paediatric AI in Germany
11th May 20182:41 pmRNSDirector Declaration
17th Apr 20183:58 pmRNSHolding(s) in Company
5th Apr 20182:08 pmRNSDirector/PDMR Shareholding
5th Apr 20188:01 amRNSDirector/PDMR Shareholding
3rd Apr 20182:39 pmRNSResult of GM and Completion of £10.5m Placing
21st Mar 20187:15 amRNSHardman & Co: New capital funds commercial plans
20th Mar 20185:20 pmRNSPlacing Update
14th Mar 20188:47 amRNSProposed Placing
12th Mar 20187:00 amRNSAppointment of CRO to support US Chronocort trials
12th Mar 20187:00 amRNSHalf-year Report
22nd Feb 20187:00 amRNSDiurnal announces grant of first patents in Japan
19th Feb 20187:00 amRNSCommercialisation agreement in Australia and NZ
13th Feb 20187:00 amRNSEuropean marketing authorisation for Alkindi®
12th Feb 20187:00 amRNSCompletion of patient enrolment in EU Phase III

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.